ProCE Banner Activity

CE / CME

Targeting HER2, HER3 and TROP2 in Breast Cancer

In this interactive on-demand Webcast, gain expert insights into current best practices and emerging data surrounding the use of HER2-, HER3-, and TROP2-targeted agents for treating metastatic breast cancer.

Physicians: Maximum of 0.75 AMA PRA Category 1 Credit

ABPath MOC : maximum of {0:0.0#} Lifelong Learning (Part II) and Self-Assessment Module (SAM) point(s)

Released: September 29, 2020

Expiration: September 28, 2021

No longer available for credit.

Share

Faculty

Mark D. Pegram

Mark D. Pegram, MD

Leonard M. Miller School of Medicine
University of Miami
Miami, Florida

Provided by

Provided by Clinical Care Options, LLC
ProCE Banner

Supporters

Supported by an educational grant from

Daiichi Sankyo, Inc.

Target Audience

This program is intended for oncologists, pathologists, and other healthcare providers who care for patients with breast, gastrointestinal, and lung cancers.

Learning Objectives

Upon completion of this activity, participants should be able to:
  • Implement best practices for HER2, HER3, and TROP2 diagnostic testing and interpretation to guide integration of the latest targeted therapies into individualized treatment plans
  • Appraise the available clinical data for established and emerging HER2-, HER3-, and TROP2-targeted therapies in breast, gastrointestinal, and lung cancers
  • Identify patients eligible to enroll on important ongoing clinical trials evaluating novel HER2-, HER3-, and TROP2-targeted therapies in breast, gastrointestinal, and lung cancers

Disclosure

Clinical Care Options, LLC (CCO) requires instructors, planners, managers, and other individuals who are in a position to control the content of this activity to disclose any relevant conflict of interest (COI) they may have as related to the content of this activity. All identified COI are thoroughly vetted and resolved according to CCO policy. CCO is committed to providing its learners with high-quality CME/CE activities and related materials that promote improvements or quality in healthcare and not a specific proprietary business interest of a commercial interest.

The faculty reported the following financial relationships or relationships to products or devices they or their spouse/life partner have with commercial interests related to the content of this CME/CE activity:

Program Director Disclosure

Program Director

Mark D. Pegram, MD

Leonard M. Miller School of Medicine
University of Miami
Miami, Florida

Mark D. Pegram, MD, has disclosed that he has received consulting fees from AstraZeneca, Daiichi Sankyo, Roche/Genentech, and Seattle Genetics.

Staff Disclosure

Staff

Megan Cartwright, PhD

Senior Clinical Editor

Megan Cartwright, PhD, has no relevant conflicts of interest to report.

Jason J. Everly, PharmD

Jason J. Everly, PharmD, has no relevant conflicts of interest to report.

Kevin Obholz, PhD

Editorial Director, Hematology/Oncology

Kevin Obholz, PhD, has no relevant conflicts of interest to report.

Timothy A. Quill, PhD

Senior Managing Editor

Timothy A. Quill, PhD, has no relevant conflicts of interest to report.

Ryan P. Topping, PhD

Associate Managing Editor

Ryan P. Topping, PhD, has no relevant conflicts of interest to report.

Instructions for Credit

Accreditation

Joint Accreditation Statement

In support of improving patient care, Clinical Care Options, LLC (CCO) is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

Physician Continuing Medical Education

Credit Designation

CCO designates this enduring material for a maximum of 0.75 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 0.75 Lifelong Learning (Part II) and Self-Assessment Module (SAM) points in the American Board of Pathology’s Maintenance of Certification (MOC) Program. Participants will earn MOC points equivalent to the amount of CME credits claimed for the activity. It is the CME activity provider’s responsibility to submit participant completion information to ACCME for the purpose of granting ABPath Continuing Certification (formerly Maintenance of Certification or MOC) credit.

Disclosure of Unlabeled Use

This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The planners of this activity do not recommend the use of any agent outside of the labeled indications.

The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of the planners. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

Disclaimer

Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications and/or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.

Additional Information

Participation in this self-study activity should be completed in approximately 0.75 hours. To successfully complete this activity and receive credit, participants must follow these steps during the period from September 29, 2020, through September 28, 2021:

1. Register online at http://www.clinicaloptions.com.
2. Read the target audience, learning objectives, and faculty disclosures.
3. Study the educational activity online or printed out.
4. Submit answers to the posttest questions and evaluation questions online.

You must receive a test score of at least 65% and respond to all evaluation questions to receive a certificate. After submitting the evaluation, you may access your online certificate by selecting the certificate link on the posttest confirmation page. Records of all CME/CE activities completed can be found on the "CME/CE Manager" page. There are no costs/fees for this activity.

Program Medium

This program has been made available online.


Goal


The goal of this activity is to improve the knowledge, competence, and performance of learners to utilize diagnostics to guide treatment of various HER2-, HER3-, and TROP2-altered cancers in the metastatic setting, including breast, gastrointestinal, and lung.